EP4565237A4 - Pharmazeutische zusammensetzungen und verwendungen davon zur behandlung von gliom - Google Patents

Pharmazeutische zusammensetzungen und verwendungen davon zur behandlung von gliom

Info

Publication number
EP4565237A4
EP4565237A4 EP23850795.8A EP23850795A EP4565237A4 EP 4565237 A4 EP4565237 A4 EP 4565237A4 EP 23850795 A EP23850795 A EP 23850795A EP 4565237 A4 EP4565237 A4 EP 4565237A4
Authority
EP
European Patent Office
Prior art keywords
gliomas
treatment
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23850795.8A
Other languages
English (en)
French (fr)
Other versions
EP4565237A1 (de
Inventor
Joshua Edward Allen
Allen Melemed
Varun Vijay Prabhu
Andrew Kang-Kang Lee
Phiroze Behram Sethna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chimerix Inc
Original Assignee
Chimerix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimerix Inc filed Critical Chimerix Inc
Publication of EP4565237A1 publication Critical patent/EP4565237A1/de
Publication of EP4565237A4 publication Critical patent/EP4565237A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP23850795.8A 2022-08-05 2023-08-04 Pharmazeutische zusammensetzungen und verwendungen davon zur behandlung von gliom Pending EP4565237A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263370520P 2022-08-05 2022-08-05
PCT/US2023/029534 WO2024030645A1 (en) 2022-08-05 2023-08-04 Pharmaceutical compositions and uses thereof for the treatment of glioma

Publications (2)

Publication Number Publication Date
EP4565237A1 EP4565237A1 (de) 2025-06-11
EP4565237A4 true EP4565237A4 (de) 2026-02-18

Family

ID=89849850

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23850795.8A Pending EP4565237A4 (de) 2022-08-05 2023-08-04 Pharmazeutische zusammensetzungen und verwendungen davon zur behandlung von gliom

Country Status (9)

Country Link
EP (1) EP4565237A4 (de)
JP (1) JP2025527300A (de)
KR (1) KR20250056926A (de)
CN (1) CN119997956A (de)
AU (1) AU2023320122A1 (de)
CA (1) CA3263675A1 (de)
IL (1) IL318680A (de)
MX (1) MX2025001423A (de)
WO (1) WO2024030645A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4684834A1 (de) * 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008302345A1 (en) * 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
RS67757B1 (sr) 2011-04-29 2026-03-31 Penn State Res Found Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
AU2020228047B2 (en) * 2019-02-27 2025-11-20 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
BR112023002082A2 (pt) * 2020-08-06 2023-05-09 Eoetvoes Lorand Tudomanyegyetem Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena
US20230285498A1 (en) * 2020-08-07 2023-09-14 City Of Hope Treatments for cancers having kras mutations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHI ANDREW S ET AL: "Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201", JOURNAL OF NEURO-ONCOLOGY, SPRINGER, BOSTON, vol. 145, no. 1, 27 August 2019 (2019-08-27), pages 97 - 105, XP036897562, ISSN: 0167-594X, [retrieved on 20190827], DOI: 10.1007/S11060-019-03271-3 *
GARDNER SHARON ET AL: "CTNI-36. SAFETY OF ONC201 ADMINISTERED TWO CONSECUTIVE DAYS PER WEEK IN PEDIATRIC H3 K27M-MUTANT GLIOMA PATIENTS", NEURO-ONCOLOGY, vol. 23, no. Supplement_6, 12 November 2021 (2021-11-12), pages vi67 - vi67, XP093347417, ISSN: 1522-8517, Retrieved from the Internet <URL:https://pmc.ncbi.nlm.nih.gov/articles/PMC8598695/> DOI: 10.1093/neuonc/noab196.259 *
MASONIC CANCER CENTER ET AL: "NCT04629209 - A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma", CLINICALTRIALS.GOV, 28 April 2021 (2021-04-28), XP093347412, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/study/NCT04629209?tab=history&a=3#version-content-panel> *
See also references of WO2024030645A1 *

Also Published As

Publication number Publication date
KR20250056926A (ko) 2025-04-28
CN119997956A (zh) 2025-05-13
JP2025527300A (ja) 2025-08-20
WO2024030645A1 (en) 2024-02-08
IL318680A (en) 2025-03-01
EP4565237A1 (de) 2025-06-11
AU2023320122A2 (en) 2025-08-14
AU2023320122A1 (en) 2025-02-20
MX2025001423A (es) 2025-07-01
CA3263675A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
EP4473970A4 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
EP4139454A4 (de) Zusammensetzungen zur behandlung von krebsmutationen und verwendungen davon
EP3952840A4 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von mentalen, verhaltensbezogen, kognitiven störungen
EP4329753A4 (de) Pharmazeutische zusammensetzungen und intravitreale wirkstofffreisetzungssysteme zur behandlung von augenerkrankungen
EP4153160A4 (de) Von benzoylhydrazid abgeleitete hdac-abbauer als therapeutika zur behandlung von krebs und anderen menschlichen erkrankungen
EP4129298C0 (de) Pharmazeutische kompositzusammensetzung zur behandlung von fibrose
EP4151227A4 (de) Pharmazeutische zusammensetzung zur behandlung von krebs
EP4469059A4 (de) Pharmazeutische zusammensetzungen aus mycophenolsäure und/oder betamethason zur behandlung von augenerkrankungen
EP4438048A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von t-zell-bedingten erkrankungen
EP4215531A4 (de) Verbindung zur prävention und behandlung von lebererkrankungen und pharmazeutische verwendung davon
EP4469033A4 (de) Pharmazeutische zusammensetzungen zur behandlung von schmerzen
EP4582087A4 (de) Pharmazeutische zusammensetzung zur behandlung von lymphomen
EP3958863C0 (de) Neuartige verbindungen und pharmazeutische zusammensetzungen daraus zur behandlung von nierenerkrankungen
ATE413171T1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz- superinfektionen und pilz-rezidiven
EP4431098A4 (de) Pharmazeutische zusammensetzung zur behandlung von alport-syndrom
EP4421077A4 (de) Aryl- oder heteroarylderivat und pharmazeutische zusammensetzung damit als wirkstoff zur prävention oder behandlung von kinasebedingten erkrankungen
EP4478887A4 (de) Neue pharmazeutische zusammensetzungen und verfahren zur behandlung von schlaflosigkeit
EP4374859A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von systemischer sklerose
EP4121084A4 (de) Zusammensetzungen zur behandlung von atemwegsinfektionen und verwendungen davon
EP4230209C0 (de) Pharmazeutische zusammensetzung, pharmazeutische kombination und kombinations-kit zur prävention oder behandlung von chronischer hepatitis b
EP4302756C0 (de) Pharmazeutische zusammensetzung enthaltend cannabidiol und etoposid zur behandlung von lungenkrebs
EP4574171A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von nierenzystischen ziliopathie
EP4452295A4 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen
EP4551220A4 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von schlaflosigkeit

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40128040

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20260120

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101AFI20260114BHEP

Ipc: A61K 31/495 20060101ALI20260114BHEP

Ipc: A61K 39/395 20060101ALI20260114BHEP

Ipc: A61P 35/00 20060101ALI20260114BHEP

Ipc: A61K 39/00 20060101ALI20260114BHEP

Ipc: C07D 471/14 20060101ALI20260114BHEP